BRAF G469R

CI-VAR-00001752Explore in graph →NP_004324.2:p.Gly469ArgNM_004333.4:c.1405G>CClinVar 13970 CIViC 840 rs121913357

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
BRAF G469R	Sorafenib	Predictive	C	Supports Sensitivity Response	2	submitted	EID1938 Case report of a patient with NSCLC and BRAF G469R mutation who showed a dramatic response to sorafenib. PMID 26237499 · Sereno et al., 2015 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13970	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Non-Hodgkin lymphoma; Cardio-facio-cutaneous syndrome	germline/somatic	3	Oct 17, 2021	clinvar